Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Polycystic Ovary Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphangioleiomyomatosis 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Colonic Neoplasms 1Chemoprevention 1Carcinoma, Hepatocellular 1

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × Resveratrol × Clear all
NCT01476592 2019-11-18

A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

University of Wisconsin, Madison

Phase NA Completed
7 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡